sub:assertion {
d:DB00289 dv:ddi-interactor-in dr:DB00289_DB00907 .
d:DB00907 dv:ddi-interactor-in dr:DB00289_DB00907 .
dr:DB00289_DB00907 dct:identifier "drugbank_resource:DB00289_DB00907" ;
dct:title "DDI between Atomoxetine and Cocaine - CYP2D6 Inhibitors (Strong) such as cocaine may increase the serum concentration of atomoxetine. Initiate atomoxetine at a reduced dose (patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor. The dose should only be increased to usual doses if symptoms fail to improve after 4 weeks. Patients established on atomoxetine therapy may require dosage reductions and should be monitored for increased levels/adverse effects with initiation/dose increase of a strong CYP2D6 inhibitor."@en ;
a dv:Drug-Drug-Interaction ;
rdfs:label "DDI between Atomoxetine and Cocaine - CYP2D6 Inhibitors (Strong) such as cocaine may increase the serum concentration of atomoxetine. Initiate atomoxetine at a reduced dose (patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor. The dose should only be increased to usual doses if symptoms fail to improve after 4 weeks. Patients established on atomoxetine therapy may require dosage reductions and should be monitored for increased levels/adverse effects with initiation/dose increase of a strong CYP2D6 inhibitor. [drugbank_resource:DB00289_DB00907]"@en .
}